Key Points
- CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics at an average price of $22.90, generating $400,750. The Rule 10b5-1 transaction reduced his stake by 8.79%, leaving him with 181,641 shares.
- The sale follows several additional insider sales by Cohlhepp in July and August, totaling more than 47,000 shares before the latest transaction.
- BCAX recently traded near $23.10, while analysts maintained a generally positive outlook: the stock has a “Moderate Buy” consensus rating and a $32.64 average price target.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Cohlhepp also recently made the following trade(s):
- On Monday, August 10th, Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock. The stock was sold at an average price of $27.98, for a total value of $524,625.00.
- On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total value of $15,544.00.
- On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total value of $817,641.72.
Bicara Therapeutics Price Performance
NASDAQ BCAX opened at $23.10 on Friday. The firm has a market capitalization of $1.53 billion, a P/E ratio of -7.45 and a beta of -0.82. Bicara Therapeutics Inc. has a 1-year low of $10.30 and a 1-year high of $30.99. The business's 50-day simple moving average is $26.01 and its 200-day simple moving average is $22.98.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.82). On average, equities research analysts expect that Bicara Therapeutics Inc. will post -3.51 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have issued reports on BCAX shares. Wells Fargo & Company boosted their price objective on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 12th. BMO Capital Markets assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, August 18th. They issued an "outperform" rating and a $35.00 target price on the stock. Wall Street Zen upgraded shares of Bicara Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, May 24th. Wedbush lifted their target price on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Bicara Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $32.64.
View Our Latest Stock Analysis on BCAX
Hedge Funds Weigh In On Bicara Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc grew its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after purchasing an additional 4,585 shares during the period. Finally, American Century Companies Inc. purchased a new position in shares of Bicara Therapeutics in the second quarter valued at $103,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
